Title:  Strategic Deal Partner (Biotech Hedge Funds)

Compensation:  20–25% Uncapped Commission + Optional Advisory Equity

Structure:  Independent Contractor / Introducer Agreement

Opportunity: Sell Risk Visibility, Not Software.

floatz uses AI to stress-test the science behind biotech programs. Our platform surfaced major toxicity red flags in Rubius ~2 years before its $200M+ collapse.

We’re expanding on the buy-side and seeking a Deal Partner to originate introductions into biotech-focused hedge funds.

This is an  access-driven  role. Not volume sales.

Who You Are

You’re already connected to PMs or pod leads. Likely backgrounds:

• Expert Networks (GLG/AlphaSights):  Ready to monetize real influence.
• Institutional / PB / Research Sales:  Fluent in Soft Dollars (28e).
• Cap Intro / HF Connector:  Your intros get taken.

You understand:

• binary events • readout risk • drawdowns • scientific failure risk • pass-through expenses

The Role

• Your job:  Book a 20-min “Risk Review” with a PM holding a biotech ticker.
• Our job:  Run the diligence, present risks, close the engagement.

You focus on origination. Not long cycles.

The Deal

• Commission:  20–25% of the first engagement (uncapped). Most initial engagements fall in the $48.5k–$145k range, translating to $10k–$36k+ per introduction .
• Equity:  Optional micro-advisory equity for consistent high-impact originators

DO NOT APPLY IF...

⛔ You want a base salary

⛔ You’ve never sold to hedge funds

⛔ You struggle with high-level biotech or investment concepts

⛔ You rely on long, multi-touch SaaS sales sequences

This is for people who can create trust-based access to decision-makers.